|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Sporanox
gptkb:Candida
gptkb:Candida_species
gptkb:Coccidioides_immitis
gptkb:Cryptococcus_neoformans
|
|
gptkbp:activities
|
inhibits fungal cell membrane synthesis
|
|
gptkbp:approves
|
gptkb:1990
gptkb:FDA
|
|
gptkbp:availability
|
widely available
|
|
gptkbp:brand
|
Diflucan
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
triazole
|
|
gptkbp:clinical_trial
|
ongoing research for new indications
|
|
gptkbp:contraindication
|
concurrent use with certain medications
hypersensitivity to fluconazole
|
|
gptkbp:developed_by
|
gptkb:Pfizer
|
|
gptkbp:dosage_form
|
gptkb:tablet
suspension
injection
150 mg for candidiasis
200 mg for cryptococcal meningitis
400 mg for severe infections
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluconazole
|
|
gptkbp:interacts_with
|
gptkb:cyclosporine
gptkb:phenytoin
gptkb:rifampin
gptkb:warfarin
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
liver function tests
renal function tests
|
|
gptkbp:is_often_used_in
|
candidiasis
cryptococcal meningitis
fungal infections in immunocompromised patients
|
|
gptkbp:is_used_for
|
fungal infections
|
|
gptkbp:lifespan
|
30 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
gptkb:fandom
dizziness
headache
nausea
abdominal pain
diarrhea
liver toxicity
skin rash
leukopenia
QT prolongation
|